Advanced Solid Tumors, Breast Cancer
Conditions
Brief summary
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended Phase 2 dose (RP2D) for subsequent Phase 2 studies. Phase 2 aims to assess the efficacy and safety of SYS6010 monotherapy or in combination with SYH2051 compared to investigator-selected chemotherapy in patients with EGFR-expressing, unresectable locally advanced or metastatic advanced breast cancer.
Detailed description
Phase Ⅰb Design: Group A (SYS6010 3.2 mg/kg, Q2W): Monotherapy Cohort: Planned enrollment of 8-12 breast cancer patients to evaluate the safety and preliminary efficacy of SYS6010 monotherapy. Combination Cohort: Includes dose-escalation and expansion phases. Dose-escalation phase: A 3+3 design will be used to explore the safety of SYS6010 combined with SYH2051, with SYH2051 doses ranging from 60-80 mg. Expansion phase: Upon completion of dose-escalation and confirmation of safety, breast cancer patients may be enrolled in the expansion phase. Group B (SYS6010 3.6 mg/kg, Q2W): Monotherapy Cohort: Planned enrollment of 8-12 breast cancer patients. Combination Cohort: Similar to Group A, with SYH2051 doses ranging from 40-60 mg. Group C (SYS6010 3.6 mg/kg, Q2W): Enroll 40 EGFR-expressing HR+/HER2- breast cancer patients to further evaluate the safety and efficacy in this specific population. Phase Ⅱ Design: Based on molecular subtypes of breast cancer, cohort studies will be conducted. Each cohort will enroll 125 patients, randomized in a 2:2:1 ratio into three groups: SYS6010 + SYH2051 SYS6010 monotherapy Chemotherapy control.
Interventions
DRUGSYS6010 jnjection
SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker
DRUGmonotherapy chemotherapy
Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)
DRUGSYH2051 tablets
SYH2051 is a Selective ATM protein kinase inhibitor
Sponsors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1b: Dose escalation and expansion Phase 2: Randomized controlled trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Age ≥ 18 years. 2. Phase 1b/Phase 2: Breast cancer (no tumor type restriction during the combination dose escalation phase). 3\. Provide tumor tissue samples for immunohistochemical EGFR expression testing, with EGFR expression positive as confirmed by the central laboratory. 4\. At least one measurable extracranial lesion according to RECIST v1.1 criteria (no requirement during the combination dose escalation phase of Phase 1b). 5\. ECOG performance status score of 0-1. 6. Expected survival ≥ 3 months. 7. Major organ function meets the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment. 8\. Subject agrees to use effective contraception from the time of signing the informed consent form until 6 months after the last dose. 9\. Willing to participate in the study, understand the study procedures, and sign a written informed consent form.
Exclusion criteria
* 1\. Active central nervous system (CNS) metastases or carcinomatous meningitis. Patients with treated and stable brain metastases are eligible for inclusion. 2\. Previously diagnosed HER2-positive breast cancer (IHC 3+ or ISH positive) (Applicable to Phase 1b Group C and Phase 2). 3\. Previously treated with antibody-drug conjugates (ADC) containing topoisomerase I inhibitors (Applicable to Phase 1b Group C and Phase 2). 4\. Allergy to any component of SYS6010 or SYH2051, or to humanized monoclonal antibodies. 5\. Allergy to any component of SYS6010 or SYH2051, or to humanized monoclonal antibodies (This is a repeat of criteria #4). 6\. Adverse events from prior antitumor therapy not recovered to ≤ Grade 1 (unless the investigator deems there is no safety risk). 7\. Failure to meet the required washout period for prior medications or treatments as specified in the protocol. 8\. History of severe cardiovascular or cerebrovascular diseases. 9. History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these conditions. 10\. Thyroid dysfunction requiring medication, unless the condition is controlled by medication and no dose adjustments are needed. 11\. Severe infection within 4 weeks prior to the first use of the investigational drug. 12\. History of discontinuing EGFR-targeted therapy for ≥ 1 month due to skin toxicity, or current skin conditions requiring medication. 13\. Gastrointestinal diseases or functional impairments that may significantly affect the absorption of the investigational drug (e.g., ulcerative disease, severe nausea/vomiting, diarrhea, malabsorption, etc.). 14\. Uncontrolled pleural or peritoneal effusion. 15. Active HBV or HCV infection, syphilis, HIV infection, or AIDS. 16. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity(DLT) occurrence and incidence | Up to approximately 3 months after the first participant is enrolled | The occurrence and incidence of dose-limiting toxicities (DLTs) will be assessed based on predefined criteria during the first 28 days after the initial dose. DLTs are defined as adverse events related to the study drug that meet the protocol-specified criteria for dose limitation. |
| Adverse events (AE) occurrence and incidence | Up to approximately 36 months after the first participant is enrolled | The occurrence and incidence of adverse events (AEs) will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. AEs will be monitored from the first dose until the safety follow-up period. |
| Objective response rate (ORR) per RECIST v1.1 | Up to approximately 36 months after the first participant is enrolled | The objective response rate (ORR) will be assessed based on RECIST v1.1 criteria. ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) as the best overall response. |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival(OS) | Up to approximately 36 months after the first participant is enrolled |
| PK parameters of toxin-bound antibody | Up to approximately 36 months after the first participant is enrolled |
| Disease control rate (DCR) per RECIST 1.1 | Up to approximately 36 months after the first participant is enrolled |
| PK parameters after single and multiple administrations of SYH2051 | Up to approximately 36 months after the first participant is enrolled |
| Description :total antibody and free toxin (JS-1) after single and continuous administration of SYS6010 | Up to approximately 36 months after the first participant is enrolled |
| Duration of response (DoR) per RECIST 1.1 | Up to approximately 36 months after the first participant is enrolled |
| Progression free survival (PFS) per RECIST 1.1 | Up to approximately 36 months after the first participant is enrolled |
Contacts
Primary ContactClinical Trials Information Group officer
Outcome results
None listed